In 2017, NICE recommended Holoclar as an option for adults with moderate-to-severe LSCD after eye burns More: First patient dosed with Chiesi’s Holoclar Source: News
read morePfizer’s Xeljanz could potentially increase the risk of blood clots. More: PRAC cautions use of Lemtrada, Xeljanz in latest meeting Source: News
read moreAbbVie’s blockbuster Humira still holds the crown for being the world’s best selling drug. More: Cosentyx ‘narrowly’ misses superiority VS Humira Source: News
read moreThe results represent a “historic” moment in cystic fibrosis care. More: ‘Impressive’ results for Trikafta in cystic fibrosis Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals